Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 283

Results For "CRO"

4634 News Found

G 20: Medical Value Travel could be focused on maintaining, improving or restoring health through medical intervention: Dr V K Paul
Policy | January 21, 2023

G 20: Medical Value Travel could be focused on maintaining, improving or restoring health through medical intervention: Dr V K Paul

There is a great opportunity for utilizing traditional medical practices like Ayurveda in Value Based Healthcare


Innova Captab gets SEBI nod to raise funds via IPO
News | January 20, 2023

Innova Captab gets SEBI nod to raise funds via IPO

The issue with a face value of Rs 10 per equity share consists of a fresh issue of equity shares worth up to Rs 400 crore


Cheplapharm selects Generis’ CARA Life Sciences platform to unify their clinical processes
News | January 20, 2023

Cheplapharm selects Generis’ CARA Life Sciences platform to unify their clinical processes

Connectivity and harmonisation were both key driving factors behind our decision to choose the CARA Life Sciences Platform to consolidate our processes


Krsnaa Diagnostics operationalized four diagnostics centres for Punjab Govt
Clinical Trials | January 19, 2023

Krsnaa Diagnostics operationalized four diagnostics centres for Punjab Govt

The company has operationalized diagnostics center at Ferozepur, Gurdaspur, Nawanshahr, and Kapurthala in Punjab.


Lupin launches Sacubitril and Valsartan combination drug for heart failure patients
News | January 19, 2023

Lupin launches Sacubitril and Valsartan combination drug for heart failure patients

Valentas and Arnipin are indicated to reduce repeated hospitalization and the risk of cardiovascular death among adult patients with chronic mild to moderate heart failure


Heart failure treatment becomes affordable with Glenmark launching Sacubitril + Valsartan tablets
News | January 18, 2023

Heart failure treatment becomes affordable with Glenmark launching Sacubitril + Valsartan tablets

Sacu V is priced at Rs. 19 per tablet for a dose of 50 mg (sacubitril 24 mg + valsartan 26 mg)


Glenmark to divest select dermatology brands for Rs. 340.48 Cr
News | January 18, 2023

Glenmark to divest select dermatology brands for Rs. 340.48 Cr

The divested brands include Onabet, Halovate, Sorvate, Luligee, Demelan, Aceret, Dosetil, Revize, and Powercort, and their sub-brands


Cipla launches Cippoint
News | January 18, 2023

Cipla launches Cippoint

Point-of-Care solution to facilitate clinicians in quick and effective decision making


AI to drive digital mammography equipment market in South Korea during 2015-2030: GlobalData
Medical Device | January 18, 2023

AI to drive digital mammography equipment market in South Korea during 2015-2030: GlobalData

AI-based medical imaging equipment firm Lunit has signed a contract to supply AI-based breast cancer screening solution “Lunit Insight MMG”


Lupin receives tentative approval from USFDA for Dolutegravir and Rilpivirine Tablets
Drug Approval | January 17, 2023

Lupin receives tentative approval from USFDA for Dolutegravir and Rilpivirine Tablets

Dolutegravir and Rilpivirine Tablets, 50 mg/25 mg, (RLD Juluca) had estimated annual sales of US $666 million in the US (IQVIA MAT September 2022)